價(jià)格 | 詢價(jià) | ||
包裝 | 20μl | 50μl | 100μl |
最小起訂量 | 1μl |
發(fā)貨地 | 上海 |
更新日期 | 2025-05-29 |
中文名稱:PML抗體 | 英文名稱:Mouse Monoclonal PML Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 7628 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Mouse |
偶聯(lián)物: 無 | 靶點(diǎn): PML |
WB | 咨詢技術(shù) | Human,Mouse,Rat |
IF | 1/100-1/200 | Human,Mouse,Rat |
IHC | 咨詢技術(shù) | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 咨詢技術(shù) | Human,Mouse,Rat |
Host/Isotype | Mouse IgG2b |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Purified recombinant fragment of human PML |
Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
Lane 1: HeLa lysate ; Lane 2: PML immunoprecipitated from HeLa lysate by P15673 ; Lane 3: The same as Lane 2 but use IgG isotype control antibody ;Result: P15673 can immunoprecipitate PML;
以下是關(guān)于PML抗體的3篇示例參考文獻(xiàn)(內(nèi)容為虛構(gòu)示例,僅供參考):
---
1. **文獻(xiàn)名稱**:*Autoantibodies against PML in Primary Biliary Cholangitis: Clinical Significance and Epitope Mapping*
**作者**:Mytilinaiou, M., et al.
**摘要**:該研究探討了原發(fā)性膽汁性膽管炎(PBC)患者血清中抗PML自身抗體的出現(xiàn)頻率及其臨床意義。通過免疫熒光和蛋白質(zhì)印跡分析,發(fā)現(xiàn)約15%的PBC患者存在抗PML抗體,且與疾病進(jìn)展相關(guān)。研究還揭示了PML蛋白的特定抗原表位可能與自身免疫反應(yīng)有關(guān)。
---
2. **文獻(xiàn)名稱**:*PML Nuclear Bodies and Viral Infection: Role of Anti-PML Antibodies in Tracking Subcellular Localization*
**作者**:Reichelt, M., et al.
**摘要**:本文利用抗PML抗體的免疫熒光技術(shù),研究了PML核體在皰疹病毒感染過程中的動態(tài)變化。研究發(fā)現(xiàn)病毒蛋白可破壞PML核體結(jié)構(gòu),而抗PML抗體能特異性標(biāo)記感染細(xì)胞中的PML聚集現(xiàn)象,為病毒-宿主相互作用機(jī)制提供了新見解。
---
3. **文獻(xiàn)名稱**:*Diagnostic Utility of Anti-PML Antibodies in Acute Promyelocytic Leukemia*
**作者**:Sternsdorf, T., et al.
**摘要**:研究評估了抗PML抗體在急性早幼粒細(xì)胞白血病(APL)診斷中的價(jià)值。通過免疫組化分析,發(fā)現(xiàn)抗PML抗體可特異性識別APL細(xì)胞中因染色體易位導(dǎo)致的PML蛋白異常聚集,為快速鑒別APL與其他白血病亞型提供了可靠工具。
---
**注**:以上文獻(xiàn)為示例,實(shí)際引用需查詢真實(shí)數(shù)據(jù)庫(如PubMed)。若需真實(shí)文獻(xiàn),建議使用關(guān)鍵詞“PML antibody”、“anti-PML autoantibody”或“PML diagnostic”在學(xué)術(shù)平臺檢索。
PML (Promyelocytic Leukemia) antibodies are autoantibodies targeting the PML protein, a key component of nuclear structures known as PML nuclear bodies (PML-NBs). These dynamic organelles play crucial roles in diverse cellular processes, including transcriptional regulation, apoptosis, DNA repair, and antiviral responses. The PML protein itself is involved in tumor suppression and genome stability, with its gene frequently disrupted in acute promyelocytic leukemia (APL) due to chromosomal translocations forming PML-RARα fusion proteins.
In autoimmune contexts, PML antibodies are primarily associated with specific subsets of autoimmune diseases, particularly in patients with dermatomyositis (DM) or systemic sclerosis (scleroderma). They are often detected alongside other myositis-specific autoantibodies, such as anti-SAE or anti-MDA5. The presence of PML antibodies may correlate with distinct clinical phenotypes, though their exact pathogenic role remains unclear. Hypotheses suggest that PML protein overexpression or aberrant immune activation in certain conditions could trigger autoantibody production.
Clinically, PML antibodies serve as diagnostic biomarkers rather than direct drivers of tissue damage. Their detection aids in subclassifying autoimmune disorders and guiding prognosis. Research continues to explore their potential role in disease mechanisms, particularly in modulating interferon signaling pathways, which are hyperactive in many autoimmune conditions. Notably, PML antibodies are distinct from the JC virus-induced PML (progressive multifocal leukoencephalopathy), a rare neurological complication in immunocompromised individuals.
成立日期 | 2024-07-02 (2年) | 注冊資本 | 20萬人民幣 |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 抗體,植物生物技術(shù),細(xì)胞培養(yǎng),蛋白組學(xué) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
武漢佰樂博生物技術(shù)有限公司
|
2025-08-01 | |
詢價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1800 |
VIP1年
|
費(fèi)雪(杭州)醫(yī)學(xué)研究有限公司
|
2025-07-28 |